Latest Balance Sheet News

Atomo Diagnostics has closed a modest Share Purchase Plan, raising $44,500 and issuing free attaching options, while reserving a substantial shortfall for future placement.

Australian Dairy Nutritionals has closed the gap on its recent Entitlement Offer by placing 25 million shortfall shares, raising an additional $0.7 million and bringing total proceeds to $1.2 million.

Kincora Copper has accelerated exploration across its Australian and Mongolian assets, leveraging new AI and quantum technology partnerships alongside partner-funded drilling, while reporting a modest net income and a strong cash position in Q1 2026.

Andean Silver has uncovered new bonanza-grade silver-gold veins near its Laguna Verde processing plant in Chile, setting the stage for a resource upgrade and feasibility studies.

Bapcor reports a turnaround in sales momentum after February 2026 but lowers its full-year earnings forecast due to geopolitical and cost pressures.

Megaport’s Latitude.sh subsidiary has secured three major AI infrastructure contracts worth USD 183 million, backed by a USD 101 million capital expenditure commitment, reinforcing its role in the global AI compute ecosystem.

Tamboran Resources has reported record gas flow rates from its Shenandoah South 6H well and secured US$188 million in a capital raise, positioning the company to deliver first gas in the Beetaloo Basin by Q3 2026.

GreenX Metals has leveraged a 2000 airborne hyperspectral survey to identify fresh high-priority tungsten, antimony, and gold targets at its Eleonore North Project in East Greenland. The discoveries sit adjacent to historical high-grade estimates, setting the stage for 2026 fieldwork aimed at advancing drill-ready targets.

Pacific Edge launches a NZ$6 million retail share offer at NZ$0.17 per share following a NZ$25.4 million institutional placement, aiming to strengthen its balance sheet and support Medicare reimbursement efforts for its bladder cancer diagnostics.

Sanford Limited delivered record half-year earnings despite a 5.5% revenue dip, driven by robust salmon and wildcatch segments, while mussel farming faced headwinds. The company cut net debt by NZ$63 million and declared a steady 5.0 cps dividend.

Neurizon Therapeutics has gained ethics approval to start a Phase 1 trial of its NUZ-001 oral liquid formulation, aiming to ease treatment for ALS patients with swallowing difficulties.

Paladin Energy Ltd (ASX:PDN) swung to a quarterly profit with US$8.4 million gross profit and bolstered its balance sheet through a A$400 million equity raise, positioning itself for expansion in uranium production and development.